Ginkgo Bioworks Holdings, Inc., known by its stock symbol DNA, has announced a reverse stock split that will take effect on August 20, 2024. The reverse split will be conducted at a ratio of 1-for-40, resulting in a change of the company's option symbol from DNA to DNA1. Following the split, the new multiplier for options will be set at 100, and the new deliverable per contract will include 2 new Class A Common Shares of Ginkgo Bioworks and cash in lieu of 0.5 fractional shares. The cash portion of the deliverable will be settled once the cash in lieu amount is determined, with the DNA component settling through the National Securities Clearing Corporation (NSCC). The Options Clearing Corporation (OCC) will oversee the settlement of the cash portion and the adjustment of options and futures as per their by-laws.

Ginkgo Bioworks Holdings, Inc., known by its stock symbol DNA, has announced a reverse stock split that will take effect on August 20, 2024. The reverse split will be conducted at a ratio of 1-for-40, resulting in a change of the company's option symbol from DNA to DNA1. Following the split, the new multiplier for options will be set at 100, and the new deliverable per contract will include 2 new Class A Common Shares of Ginkgo Bioworks and cash in lieu of 0.5 fractional shares. The cash portion of the deliverable will be settled once the cash in lieu amount is determined, with the DNA component settling through the National Securities Clearing Corporation (NSCC). The Options Clearing Corporation (OCC) will oversee the settlement of the cash portion and the adjustment of options and futures as per their by-laws.